Facing Shortage, Novo Nordisk Halts All Marketing for Wegovy
Advertising pause aims to prevent stimulating further demand, company says.
Novo Nordisk, a Danish pharmaceutical company, is pausing all advertising efforts for Wegovy, a drug prescribed for obesity, in an effort to curb growing demand. The organization believes that the popularity of this medication is due to its promotion as a weight-loss panacea by influencers on social media, mainly TikTok.
In addition to slowing down advertisements, there have been production issues. In April, Novo said it would increase the supply of Wegovy after initial contract manufacturing difficulties.
According to the company, promotional efforts aimed at healthcare professionals are also being assessed for potential adjustments.
Reference: Shortage of Wegovy Leads Novo Nordisk to Pause All Advertisements. May 23, 2023/Health News
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
